Drug discovery in the ubiquitin - Proteasome system

Grzegorz Nalepa, Mark Rolfe, J. Wade Harper

Research output: Contribution to journalArticle

447 Citations (Scopus)

Abstract

Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.

Original languageEnglish (US)
Pages (from-to)596-613
Number of pages18
JournalNature Reviews Drug Discovery
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2006

Fingerprint

Proteasome Endopeptidase Complex
Drug Discovery
Ubiquitin
Cell Cycle Checkpoints
Neurodegenerative Diseases
Proteolysis
Neoplasms
Pharmacology
Proteins
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Drug discovery in the ubiquitin - Proteasome system. / Nalepa, Grzegorz; Rolfe, Mark; Harper, J. Wade.

In: Nature Reviews Drug Discovery, Vol. 5, No. 7, 01.07.2006, p. 596-613.

Research output: Contribution to journalArticle

Nalepa, Grzegorz ; Rolfe, Mark ; Harper, J. Wade. / Drug discovery in the ubiquitin - Proteasome system. In: Nature Reviews Drug Discovery. 2006 ; Vol. 5, No. 7. pp. 596-613.
@article{dd0f844264514f3d876d7286e0bd10de,
title = "Drug discovery in the ubiquitin - Proteasome system",
abstract = "Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.",
author = "Grzegorz Nalepa and Mark Rolfe and Harper, {J. Wade}",
year = "2006",
month = "7",
day = "1",
doi = "10.1038/nrd2056",
language = "English (US)",
volume = "5",
pages = "596--613",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Drug discovery in the ubiquitin - Proteasome system

AU - Nalepa, Grzegorz

AU - Rolfe, Mark

AU - Harper, J. Wade

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.

AB - Regulated protein turnover via the ubiquitin-proteasome system (UPS) underlies a wide variety of signalling pathways, from cell-cycle control and transcription to development. Recent evidence that pharmacological inhibition of the proteasome can be efficacious in the treatment of human cancers has set the stage for attempts to selectively inhibit the activities of disease-specific components of the UPS. Here, we review recent advances linking UPS components with specific human diseases, most prominently cancer and neurodegenerative disorders, and emphasize potential sites of therapeutic intervention along the regulated protein-degradation pathway.

UR - http://www.scopus.com/inward/record.url?scp=33745674468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745674468&partnerID=8YFLogxK

U2 - 10.1038/nrd2056

DO - 10.1038/nrd2056

M3 - Article

C2 - 16816840

AN - SCOPUS:33745674468

VL - 5

SP - 596

EP - 613

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 7

ER -